Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Buprenorphine
Viatris UK Healthcare Ltd
N02AE01
Buprenorphine
35microgram/1hour
Transdermal patch
Transdermal
Schedule 3 (CD No Register)
Caution - AMP level prescribing advised
BNF: 04070200; GTIN: 5016695006987
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT BUPLAST 35 MICROGRAMS/H TRANSDERMAL PATCH BUPLAST 52.5 MICROGRAMS/H TRANSDERMAL PATCH BUPLAST 70 MICROGRAMS/H TRANSDERMAL PATCH READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Buplast is and what it is used for 2. What you need to know before you use Buplast 3. How to use Buplast 4. Possible side effects 5. How to store Buplast 6. Contents of the pack and other information 1. WHAT BUPLAST IS AND WHAT IT IS USED FOR The active substance of Buplast is buprenorphine. Buplast is an analgesic (a pain-relieving medicine) intended to relieve moderate to severe cancer pain and severe pain that has not responded to other types of painkillers. Buplast acts through the skin. Buprenorphine is an opioid (strong pain reliever), which reduces pain by acting on the central nervous system (specific nerve cells in the spinal cord and in the brain). The effect of the transdermal patch lasts for up to four days. Buplast is not suitable for the treatment of acute (short-lasting) pain. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE BUPLAST DO NOT USE BUPLAST - if you are allergic to buprenorphine or any of the other ingredients of this medicine (listed in section 6). - if you are dependent on strong pain relievers (opioids); - if you suffer from a disease in which you have or may have great difficulty breathing - if you are taking monoamine oxidase (MAO) inhibitors (certain medicines used to treat depression or Parkinson’s disease such as moclobemide,selegiline) or you have t Read the complete document
OBJECT 1 BUPLAST 35 MICROGRAMS/H TRANSDERMAL PATCH Summary of Product Characteristics Updated 13-Jul-2017 | Generics UK T/A Mylan 1. Name of the medicinal product Buplast 35 micrograms/h transdermal patch 2. Qualitative and quantitative composition Each transdermal patch contains 20 mg buprenorphine. Area containing the active substance: 25 cm 2 Nominal release rate: 35 micrograms of buprenorphine per hour (over a period of 96 hours). For the full list of excipients, see section 6.1. 3. Pharmaceutical form Transdermal patch Rectangular beige coloured patch with rounded edges and imprinted with “Buprenorphin” and “35 μg/h” in blue colour. 4. Clinical particulars 4.1 Therapeutic indications Moderate to severe cancer pain and severe pain which does not respond to non-opioid analgesics. Buplast is not suitable for the treatment of acute pain. 4.2 Posology and method of administration Posology _Patients over 18 years of age_ The dose should be adapted to the condition of the individual patient (pain intensity, suffering, individual reaction) and checked at regular intervals. The lowest possible dose providing adequate pain relief should be given. Three transdermal patch strengths are available to provide such adaptive treatment: Buplast 35 micrograms/h, Buplast 52.5 micrograms/h and Buplast 70 micrograms/h. _Initial dose selection_: patients who have previously not received any analgesics should start with the lowest transdermal patch strength (Buplast 35 micrograms/h). Patients previously given a WHO step-I analgesic (non-opioid) or a step-II analgesic (weak opioid) should also begin with Buplast 35 micrograms/h. According to the WHO recommendations, the administration of a non-opioid analgesic can be continued, depending on the patient's overall medical condition. When switching from a step-III analgesic (strong opioid) to Buplast and choosing the initial transdermal patch strength, the nature of the previous medicinal product, administration and the mean daily dose should be taken into account in order to Read the complete document